Business Context and Reporting Period
Company: VistaGen Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2015
Business Description: Clinical-stage biopharmaceutical company focused on developing treatments for Major Depressive Disorder (MDD) and other CNS-related indications.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational and clinical developments rather than financial performance.
Material Changes and Operational Updates
- Publication of Pre-clinical Data: Pre-clinical data for the lead pipeline candidate, AV-101 (an orally-available prodrug), will be published in the October 2015 issue of the Journal of Pharmacology and Experimental Therapeutics.
- Study Findings: The article, titled "The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition," suggests AV-101 may offer antidepressant effects similar to ketamine without associated side effects.
- Regulatory Clearance: In July 2015, the Company received clearance from the U.S. FDA and NIH to initiate an NIH-funded Phase 2 clinical study of AV-101 in subjects with treatment-resistant MDD.
- Study Leadership: The Principal Investigator for the Phase 2 study is Dr. Carlos Zarate, Jr., Chief of Experimental Medicine at the NIMH.
Guidance, Outlook, and Risks
Outlook: The Company is advancing AV-101 into Phase 2 clinical trials for treatment-resistant MDD, supported by NIH funding and recent regulatory clearances.
Risks and Contingencies: The filing does not explicitly detail financial risks or contingencies. As a clinical-stage company, inherent risks include the uncertainty of clinical trial outcomes and regulatory approval processes, though these are not elaborated in this specific 8-K text.
Key Facts for Investor Verification
- Verify the publication date and full content of the article in the Journal of Pharmacology and Experimental Therapeutics.
- Confirm the enrollment status and timeline of the NIH-funded Phase 2 clinical study for AV-101.
- Review the Company's cash position and burn rate in subsequent filings (e.g., 10-Q or 10-K) as this 8-K contains no financial data.
- Monitor FDA and NIH communications regarding the progress of the Phase 2 trial.